This systematic review evaluates mitochondrial biomarkers, highlighting GDF-15 and FGF-21 as the most promising candidates for diagnosing and managing mitochondrial disorders. Although these biomarkers demonstrate potential, their reliability varies across conditions, underscoring the need for further validation. Improved biomarker validation would enable earlier detection, better disease monitoring, and more precise
